Racial/Ethnic Differences in Treatment Utilization for ATTR Amyloidosis PC120 (#241)
Alexandra Greatsinger(Analysis Group (United States)), Vaishali Sanchorawala(Boston Medical Center), Lisa Mendelson(Boston University), L John, James Signorovitch(Analysis Group (United States)), Tracy Joshi(Boston University), Andrew Staron(Boston University), Jessica Smith(University of Florida), Natasha Burke(Boston University), Brian Spencer(Boston University), Nadia Tabatabaeepour(Analysis Group (United States)), Tatiana Prokaeva(Boston University)
Cited by 0
Related Papers
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
|Circulation|2018|837
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
|Annals of Internal Medicine|2004|615
Systemic immunoglobulin light chain amyloidosis
|Nature Reviews Disease Primers|2018|550